文献速递肿瘤 PET/CT甲状腺核医学

18F-氟雌二醇PET/CT评估乳腺癌雌激素受体状态及其瘤内异质性

The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
PubMed 文献 · Clin Nucl Med · 2017-01-01

回顾性纳入46例女性患者共50个经组织学证实的浸润性乳腺癌病灶,均接受18F-FES与18F-FDG PET/CT。F-FES摄取与ER、孕激素受体、人表皮生长因子受体2表达一致性良好(P<0.001)。ROC曲线确定鉴别ER阳性与阴性病灶的最佳阈值为SUVmax 1.82(敏感度88.2%、特异度87.5%)和SUVmean 1.21(敏感度85.3%、特异度93.7%)。

要点

  • F-FES PET/CT鉴别ER阳性与阴性病灶的SUVmax阈值为1.82,敏感度88.2%、特异度87.5%。
  • SUVmean阈值1.21的敏感度85.3%、特异度93.7%,用SUVmean代替SUVmax相关性略好。
  • 简化的异质性指数-FES可观察ER异质性,复发/转移患者及非乳腺部位病灶异质性可能更大。

核心结论

  • F-FES PET/CT是评估乳腺癌患者ER表达可行的无创方法。
  • 由于存在瘤内异质性,F-FES PET/CT可能更好地反映ER表达,尤其在治疗后的转移患者中,从而辅助制定个体化治疗决策。

研究设计与样本

  • 回顾性纳入本中心46例女性患者共50个经组织学证实的浸润性乳腺癌病灶,均接受18F-FES与18F-FDG PET/CT,所有入组患者计划接受活检。

主要发现

  • F-FES摄取与ER、孕激素受体、人表皮生长因子受体2表达一致性良好(P<0.001),用SUVmean代替SUVmax可提供略好的相关性。
  • ROC曲线分析确定F-FES PET/CT鉴别ER阳性与阴性病灶的最佳阈值为SUVmax 1.82(敏感度88.2%、特异度87.5%)和SUVmean 1.21(敏感度85.3%、特异度93.7%)。
  • 简化的异质性指数-FES可简便观察ER异质性,结果提示复发/转移患者及位于乳腺以外部位的病灶异质性可能更大。

关键数值与推荐

  • F-FES PET/CT鉴别ER阳性与ER阴性病灶的SUVmax最佳阈值为1.82,敏感度88.2%、特异度87.5%。
  • F-FES PET/CT鉴别ER阳性与ER阴性病灶的SUVmean最佳阈值为1.21,敏感度85.3%、特异度93.7%。
  • F-FES摄取与ER、孕激素受体、人表皮生长因子受体2表达的一致性检验P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of this study was to investigate the clinical value of F-fluoroestradiol (F-FES) PET/CT in the assessment of the estrogen receptor (ER) and its intratumoral heterogeneity in breast cancer patients. METHODS: Forty-six female patients (50 lesions) with histologically confirmed invasive breast cancer who underwent both F-FES and F-FDG PET/CT in our center were retrospectively included. All the patients enrolled were scheduled to undergo biopsy. The F-FES and FDG uptakes were compared with pathological features (tumor size, ER, progesterone receptor, human epidermal growth factor receptor 2, and Ki67%). The optimal threshold to discriminate ER-positive and ER-negative lesions was determined by receiver operating characteristic curve analysis. Furthermore, we observed the intratumoral heterogeneity by a heterogeneity index (SUVmax/SUVmean) and compared the results with the Chang-Gung Image Texture Analysis. RESULTS: There was good agreement between F-FES uptake and ER, progesterone receptor, and human epidermal growth factor receptor 2 expression (P < 0.001), and the use of SUVmean instead of SUVmax can provide a slightly better correlation. The optimal threshold for F-FES PET/CT to discriminate between ER-positive and ER-negative lesions, as determined by receiver operating characteristic curve analysis, was an SUVmax of 1.82 (sensitivity = 88.2% and specificity = 87.5%) and SUVmean of 1.21 (sensitivity = 85.3% and specificity = 93.7). Our simplified heterogeneity index-FES can easily observe ER heterogeneity. In addition, our results suggested that recurrent/metastatic patients and lesions located other than breast might have greater heterogeneity. CONCLUSIONS: F-FES PET/CT is a feasible, noninvasive method for assessing ER expression in breast cancer patients. Because intratumoral heterogeneity exists, F-FES PET/CT might better reflect the ER expression, especially in metastatic patients after treatment, thus assisting in making individualized treatment decisions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Yang Z, Sun Y, Xu X, et al. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT. Clin Nucl Med. 2017. PMID: 28221191. doi:10.1097/RLU.0000000000001587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。